Medizone's Blood Decontamination Technology Proven Successful in Canadian Monkey Trail. New York, June 2, 1993 -- Medizone International, Inc. (OTC) today announced the successful completion of the first two phases of a Canadian research project that has demonstrated preliminary scientific evidence supporting the use of the Company's proprietary blood decontamination technology in a live, primate (monkey) model. In making the announcement, Medizone president, Dr. Joseph S. Latino said, "To date, the research program has successfully demonstrated that monkeys receiving blood fractionated plasma, purposely infected with a highly virulent strain of Simian Immunodeficiency virus (monkey equivalent to HIV), but treated with Medizone's process, did not demonstrate any signs of infection over the course of the study (35 days). However, all animals receiving similarly infected products without the benefit of intervention of Medizone's decontamination technology died within 12-14 days. "These preliminary research results indicate the capability of Medizone's patented scientific and technological process to inactivate blood and blood products of certain viral contaminants, including the AIDS virus," Dr. Latino continued. This research project was under the direction of an international collaborative team of scientists representing the Canadian Red Cross, Canadian Departments of Defense and Agriculture, Cornell University Veterinarian Medical College and Medizone Canada Ltd. Medizone International, Inc. is developing, MEDIZONE (Trademark), an ozone-based treatment for diseases caused by lipid enveloped viruses, including Acquired Immunodeficiency Syndrome (AIDS), hepatitis B, and herpes; and is also developing its patented technology for the decontamination of blood and blood products.